放射性核素在嗜铬细胞瘤诊断与治疗中的应用进展

张紫薇; 程刚; 张紫薇; 程刚

doi:10.3760/cma.j.issn.1673-4114.2019.01.014

[1]

Vallabhajosula S, Nikolopoulou A. Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology[J]. Semin Nucl MedSemin Nucl Med, 2011, 41(5): 324-333. doi: 10.1053/j.semnuclmed.2011.05.003

[2]

董峰. 核素¹³¹I标记MIBG体内示踪诊断嗜铬细胞瘤[J]. 甘肃医药, 2012, 31(9): 678-679. doi: 10.3969/j.issn.1004-2725.2012.09.017
Dong F. ¹³¹I-labeled MIBG in vivo tracer diagnosis of pheochromocytoma[J]. Gansu Med JGansu Med J, 2012, 31(9): 678-679. doi: 10.3969/j.issn.1004-2725.2012.09.017

[3]

Wieland DM, Wu J, Brown LE, et al. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [¹³¹I]iodobenzylguanidine[J]. J Nucl Med, 1980, 21(4):349-353.

[4]

张迎强, 陈黎波, 李方, 等. ¹³¹I-MIBG显像诊断嗜铬细胞瘤[J]. 中国医学影像技术, 2009, 25(7): 1283-1285. doi: 10.3321/j.issn:1003-3289.2009.07.046
Zhang YQ, Chen LB, Li F, et al. Application of ¹³¹I-MIBG scintigraphy in diagnosis of pheochromocytoma[J]. Chin J Med Imaging TechnolChin J Med Imaging Technol, 2009, 25(7): 1283-1285. doi: 10.3321/j.issn:1003-3289.2009.07.046

[5]

Pappachan JM, Raskauskiene D, Sriraman R, et al. Diagnosis and management of pheochromocytoma: a practical guide to clinicians[J]. Curr Hypertens RepCurr Hypertens Rep, 2014, 16(7): 442-. doi: 10.1007/s11906-014-0442-z

[6]

Baez JC, Jagannathan JP, Krajewski K, et al. Pheochromocytoma and paraganglioma: imaging characteristics[J]. Cancer ImagingCancer Imaging, 2012, 12: 153-162. doi: 10.1102/1470-7330.2012.0016

[7]

Tiwari A, Shah N, Sarathi V, et al. Genetic status determines ¹⁸F-FDG uptake in pheochromocytoma/paraganglioma[J]. J Med Imaging Radiat OncolJ Med Imaging Radiat Oncol, 2017, 61(6): 745-752. doi: 10.1111/1754-9485.12620

[8]

Chang CA, Pattison DA, Tothill RW, et al. ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity[J]. Cancer ImagingCancer Imaging, 2016, 16: 22-. doi: 10.1186/s40644-016-0084-2

[9]

Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma[J]. J Clin OncolJ Clin Oncol, 2007, 25(16): 2262-2269. doi: 10.1200/JCO.2006.09.6297

[10]

Fikri AS, Kroiss A, Ahmad Z, et al. Localization and prediction of malignant potential in recurrent pheochromocytoma/paraganglioma(PCC/PGL)using ¹⁸F-FDG PET/CT[J]. Acta RadiologicaActa Radiologica, 2014, 55(5): 631-640. doi: 10.1177/0284185113504330

[11]

Pacak K, Eisenhofer G, Carrasquillo JA, et al. 6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma[J]. HypertensionHypertension, 2001, 38(1): 6-8. doi: 10.1161/01.HYP.38.1.6

[12]

Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus[131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2003, 88(9): 4083-4087. doi: 10.1210/jc.2003-030235

[13]

林薇, 李红. 嗜铬细胞瘤定位核素诊断方法的研究进展[J]. 国际内分泌代谢杂志, 2006, 26(6): 418-420. doi: 10.3760/cma.j.issn.1673-4157.2006.06.017
Lin W, Li H. The radionuclide imaging methods for the diagnostic localization of pheochromocytoma[J]. Int J Endocrinol MetabInt J Endocrinol Metab, 2006, 26(6): 418-420. doi: 10.3760/cma.j.issn.1673-4157.2006.06.017

[14]

贾丽娜, 张岚. ¹⁸F-DOPA制备研究进展[J]. 同位素, 2017, 30(1): 71-77. doi: 10.7538/tws.2017.30.01.0071
Jia LN, Zhang L. Research Progress in the Preparation of ¹⁸F-DOPA[J]. Journal of IsotopesJournal of Isotopes, 2017, 30(1): 71-77. doi: 10.7538/tws.2017.30.01.0071

[15]

Hoegerle S, Nitzsche E, Altehoefer C, et al. Pheochromocytomas: detection with ¹⁸F DOPA whole body PET--initial results[J]. RadiologyRadiology, 2002, 222(2): 507-512. doi: 10.1148/radiol.2222010622

[16]

Zanzi I, Studentsova Y, Bjelke D, et al. Fluorine-18-fluorodihydroxyphenylalanine Positron-emission Tomography Scans of Neuroendocrine Tumors (Carcinoids and Pheochromocytomas)[J]. J Clin Imaging SciJ Clin Imaging Sci, 2017, 7: 20-. doi: 10.4103/jcis.JCIS_107_16

[17]

景红丽, 李方. 生长抑素受体显像和治疗在神经内分泌肿瘤方面的临床应用[J]. 中国医学影像学杂志, 2004, 12(4): 296-299. doi: 10.3969/j.issn.1005-5185.2004.04.019
Jing HL, Li F. Clinical application of somatostatin receptor imaging and therapy in neuroendocrine tumors[J]. Chinese J Med ImagingChinese J Med Imaging, 2004, 12(4): 296-299. doi: 10.3969/j.issn.1005-5185.2004.04.019

[18]

潘慧, 史轶蘩. 生长抑素受体显像在内分泌临床的应用[J]. 国外医学内分泌学分册, 2002, 22(5): 289-292. doi: 10.3760/cma.j.issn.1673-4157.2002.05.011
Pan H, Shi YF. Clinical application of somatostatin receptor imaging in endocrine[J]. Section Endocrinol Foreign Med SciSection Endocrinol Foreign Med Sci, 2002, 22(5): 289-292. doi: 10.3760/cma.j.issn.1673-4157.2002.05.011

[19]

van der Harst E, de Herder WW, Bruining HA, et al. [¹²³I]metaiodobenzylguanidine and [¹¹¹In]octreotide uptake in begnign and malignant pheochromocytomas[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2001, 86(2): 685-693. doi: 10.1210/jc.86.2.685

[20]

陈黎波, 李方, 景红丽, 等. ⁹⁹Tc^m-HTOC和¹³¹Ⅰ-MIBG显像诊断嗜铬细胞瘤的比较[J]. 中华核医学与分子影像杂志, 2006, 26(1): 26-28. doi: 10.3760/cma.j.issn.2095-2848.2006.01.008
Chen LB, Li F, Jing HL, et al. A comparative study of ⁹⁹Tc^m-HTOC and ¹³¹I-MIBG in diagnosing pheochromocytoma[J]. Chin J Nucl MedChin J Nucl Med, 2006, 26(1): 26-28. doi: 10.3760/cma.j.issn.2095-2848.2006.01.008

[21]

赵晓斌. ⁶⁸Ga-DOTATATE和¹⁸F-FDG PET/CT显像在垂体瘤中的临床应用研究[D]. 北京: 北京协和医学院, 2014.

Zhao XB. Clinical application of ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT imaging in pituitary tumor[D]. Beijing: Peking Union Medical College, 2014.

[22]

Janssen I, Blanchet EM, Adams K, et al. Superiority of [⁶⁸Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma[J]. Clin Cancer ResClin Cancer Res, 2015, 21(17): 3888-3895. doi: 10.1158/1078-0432.CCR-14-2751

[23]

Archier A, Varoquaux A, Garrigue P, et al. Prospective comparison of ⁶⁸Ga-DOTATATE and ¹⁸F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2016, 43(7): 1248-1257. doi: 10.1007/s00259-015-3268-2

[24]

李方. ⁶⁸Ga标记显像剂的发展: 核医学的进步与契机[J]. 中华核医学与分子影像杂志, 2017, 37(3): 129-131. doi: 10.3760/cma.j.issn.2095-2848.2017.03.001
Li F. ⁶⁸Ga-radiopharmacueticals development: advances and opportunities of nuclear medicine[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2017, 37(3): 129-131. doi: 10.3760/cma.j.issn.2095-2848.2017.03.001

[25]

罗琼, 罗全勇, 朱瑞森, 等. ¹³¹I-间碘苄胍治疗94例恶性嗜铬细胞瘤转移灶25年随访的疗效评价[J]. 中国医药导报, 2011, 8(32): 29-30, 90. doi: 10.3969/j.issn.1673-7210.2011.32.011
Luo Q, Luo QY, Zhu RS, et al. Efficacy evaluation of 25-year follow-up in 94 cases of malignant pheochromocytoma with metastases treated by ¹³¹I-meta-iodo benzyl guanidine[J]. China Medical HeraldChina Medical Herald, 2011, 8(32): 29-30, 90. doi: 10.3969/j.issn.1673-7210.2011.32.011

[26]

Rufini V, Treglia G, Perotti G, et al. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas[J]. Hormones(Athens)Hormones(Athens), 2013, 12(1): 58-68.

[27]

Sisson J, Shapiro B, Beierwaltes WH, et al. Treatment of malignant pheochromocytoma with a new radiopharmaceutical[J]. Trans Assoc Am PhysiciansTrans Assoc Am Physicians, 1983, 96: 209-217.

[28]

Carrasquillo JA, Pandit-Taskar N, Chen CC. I-131 Metaiodobenzylguanidine Therapy of Pheochromocytoma and Paraganglioma[J]. Semin Nucl MedSemin Nucl Med, 2016, 46(3): 203-214. doi: 10.1053/j.semnuclmed.2016.01.011

[29]

Giammarile F, Chiti A, Lassmann M, et al. EANM procedure guidelines for ¹³¹I-meta-iodobenzylguanidine (¹³¹I-MIBG) therapy[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2008, 35(5): 1039-1047. doi: 10.1007/s00259-008-0715-3

[30]

中华医学会内分泌学分会肾上腺学组. 嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识[J]. 中华内分泌代谢杂志, 2016, 32(3): 181-187. DOI: 10.3760/cma.j.issn.1000-6699.2016.03.002.

Chinese Society of Endocrinology Adrenal Gland Group. Expert consensus on the diagnosis and treatment of pheochromocytoma and paraganglioma[J]. Chin J Endocrinol Metab, 2016, 32(3): 181-187. DOI: 10.3760/cma.j.issn.1000-6699.2016.03.002.

[31]

van Hulsteijn LT, Niemeijer ND, Dekkers OM, et al. ¹³¹I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis[J]. Clin Endocrinol (Oxf)Clin Endocrinol (Oxf), 2014, 80(4): 487-501. doi: 10.1111/cen.12341

[32]

臧士明, 艾书跃, 姚晓晨, 等. ¹⁸F-FDG及⁶⁸Ga-DOTA-NOC PET/CT对G3神经内分泌肿瘤的诊断比较[J]. 中华核医学与分子影像杂志, 2017, 37(4): 202-206. doi: 10.3760/cma.j.issn.2095-2848.2017.04.003
Zang SM, Ai SY, Yao XC, et al. Comparison of ¹⁸F-FDG and ⁶⁸Ga-DOTA-NOC PET/CT on the diagnosis of G3 neuroendocrine neoplasm[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2017, 37(4): 202-206. doi: 10.3760/cma.j.issn.2095-2848.2017.04.003

[33]

Pinato DJ, Black JR, Ramaswami R, et al. Peptide receptor radionuclide therapy for metastatic paragangliomas[J]. Med OncolMed Oncol, 2016, 33(5): 47-. doi: 10.1007/s12032-016-0737-9